21 Sep
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
WATERTOWN, Mass. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s
20 Sep
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
WATERTOWN, Mass. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin
09 Sep
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
WATERTOWN, Mass. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
08 Sep
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level
12 Aug
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021;   Manufacturing issue has been resolved, with a new completed lot undergoing final release testing SEL-399 (empty AAV8 capsid
05 Aug
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
WATERTOWN, Mass. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a
02 Aug
Selecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
26 Jul
Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia
– Selecta appoints gene therapy pioneer Jude Samulski , Ph.D. as a special advisor to help guide Selecta’s gene therapy programs into the clinic – – Data demonstrate that ImmTOR enhances transgene expression after both initial and repeat dosing – –  Publication further validates use of ImmTOR in
08 Jul
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
WATERTOWN, Mass. , July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
24 Jun
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
WATERTOWN, Mass. , June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced   the appointment of